Spatiotemporal genomic architecture informs precision oncology in glioblastoma

Nature Genetics

Volumn 49, Issue 4, 2017, Pages 594-599

  Lee, Jin Ku ^a   Wang, Jiguang ^b,c   Sa, Jason K ^a,d   Ladewig, Erik ^b   Lee, Hae Ock ^a   Lee, In Hee ^a   Kang, Hyun Ju ^a   Rosenbloom, Daniel S ^b   Camara, Pablo G ^b   Liu, Zhaoqi ^b   Van Nieuwenhuizen, Patrick ^b   Jung, Sang Won ^a,d   Choi, Seung Won ^a,d   Kim, Junhyung ^a   Chen, Andrew ^b   Kim, Kyu Tae ^a   Shin, Sang ^a,d   Seo, Yun Jee ^a   Oh, Jin Mi ^a   Shin, Yong Jae ^a   Park, Chul Kee ^e   Kong, Doo Sik ^a   Seol, Ho Jun ^a   Blumberg, Andrew ^f   Lee, Jung Il ^a   Iavarone, Antonio ^b   Park, Woong Yang ^a,d   Rabadan, Raul ^b   Nam, Do Hyun ^a,d   more..

^a Samsung Medical Center   (South Korea)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^d Sungkyunkwan University   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CYTOARCHITECTURE; GENE MUTATION; GENE TARGETING; GENETIC DISTANCE; GENETIC HETEROGENEITY; GENETIC SIMILARITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PHYLOGENETIC TREE; PRIORITY JOURNAL; SPATIOTEMPORAL ANALYSIS; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; WHOLE EXOME SEQUENCING; BRAIN TUMOR; GENETICS; GENOMICS; MUTATION; PROCEDURES;

PHOSPHATIDYLINOSITOL 3 KINASE;

BRAIN NEOPLASMS; GENOMICS; GLIOBLASTOMA; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PRECISION MEDICINE;

EID: 85014515130     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3806     Document Type: Article

References (51)

1. Hamburg, M.A. & Collins, F.S. The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
2. Brennan, C.W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
3. Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550-563 (2016).
4. Cloughesy, T.F., Cavenee, W.K. & Mischel, P.S. Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 9, 1-25 (2014).
5. Frattini, V. et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141-1149 (2013).
6. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011).
7. Szerlip, N.J. et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 109, 3041-3046 (2012).
8. Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25, 316-327 (2015).
9. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 110, 4009-4014 (2013).
10. Patel, A.P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
11. Kumar, A. et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 15, 530 (2014).
12. Johnson, B.E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
13. Yates, L.R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
14. Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768-776 (2016).
15. Ohka, F., Natsume, A. & Wakabayashi, T. Current trends in targeted therapies for glioblastoma multiforme. Neurol. Res. Int. 2012, 878425 (2012).
16. Kim, J. et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28, 318-328 (2015).
17. Liu, Q. et al. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol. 130, 587-597 (2015).
18. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235 (2012).
19. Hartmann, C., Bartels, G., Gehlhaar, C., Holtkamp, N. & von Deimling, A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol. 109, 639-642 (2005).
20. Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209-216 (2015).
21. Koren, S. et al. PIK3CAH1047R induces multipotency and multi-lineage mammary tumours. Nature 525, 114-118 (2015).
22. Carlsson, G. Topology and data. Bull. Amer. Math. Soc. 46, 255-308 (2009).
23. Singh, G., Memoli, F. & Carlsson, G.E. Topological methods for the analysis of high dimensional data sets and 3D object recognition. in SPBG (eds. Botsch, M. & Pajarola, R.) 91-100 (Citeseer, 2007).
24. Moiyadi, A., Syed, P. & Srivastava, S. Fluorescence-guided surgery of malignant gliomas based on 5-aminolevulinic acid: paradigm shifts but not a panacea. Nat. Rev. Cancer 14, 146 (2014).
25. Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392-401 (2006).
26. Ozawa, T. et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26, 288-300 (2014).
27. Merzak, A., Koocheckpour, S. & Pilkington, G.J. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 54, 3988-3992 (1994).
28. Yoshida, T., Matsuda, Y., Naito, Z. & Ishiwata, T. CD44 in human glioma correlates with histopathological grade and cell migration. Pathol. Int. 62, 463-470 (2012).
29. Joo, K.M. et al. MET signaling regulates glioblastoma stem cells. Cancer Res. 72, 3828-3838 (2012).
30. Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
31. Kinzler, K.W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
32. Verhaak, R.G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
33. Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403 (2006).
34. Clark, K. et al. The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J. Digit. Imaging 26, 1045-1057 (2013).
35. Wangaryattawanich, P. et al. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro-oncol. 17, 1525-1537 (2015).
36. Rios Velazquez, E. et al. Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features. Sci. Rep. 5, 16822 (2015).
37. Giannopoulos, S. & Kyritsis, A.P. Diagnosis and management of multifocal gliomas. Oncology 79, 306-312 (2010).
38. Kyritsis, A.P., Levin, V.A., Yung, W.K. & Leeds, N.E. Imaging patterns of multifocal gliomas. Eur. J. Radiol. 16, 163-170 (1993).
39. Zinn, P.O. et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One 6, e25451 (2011).
40. Li, Y.M., Suki, D., Hess, K. & Sawaya, R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J. Neurosurg. 124, 977-988 (2016).
41. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
42. Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458-468 (2015).
43. Li, B. & Dewey, C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
44. Iyer, M.K., Chinnaiyan, A.M. & Maher, C.A. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903-2904 (2011).
45. Cahoy, J.D. et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 28, 264-278 (2008).
46. Butovsky, O. et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131-143 (2014).
47. Bhasin, M. et al. Bioinformatic identification and characterization of human endothelial cell-restricted genes. BMC Genomics 11, 342 (2010).
48. Chtanova, T. et al. Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J. Immunol. 175, 7837-7847 (2005).
49. Abbas, A.R. et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 6, 319-331 (2005).
50. Huang, S. & Pang, L. Comparing statistical methods for quantifying drug sensitivity based on in vitro dose-response assays. Assay Drug Dev. Technol. 10, 88-96 (2012).
51. Zairis, S. et al. Moduli spaces of phylogenetic trees describing tumor evolutionary patterns. Lect. Notes Comput. Sci. 8609, 528-539 (2014).